Tag
This study reveals that lifelong genetic differences in LDL cholesterol levels do not significantly affect the risk of venous thromboembolism (VTE), suggesting LDL-C may not be a major causal factor in VTE development.
Evolocumab significantly reduces first and subsequent major adverse cardiovascular events in high-risk patients without prior myocardial infarction or stroke, affirming the benefit of intensive LDL-C lowering for cumulative cardiovascular r
This observational study shows PCSK9 inhibitor monoclonal antibodies significantly reduce ischaemic events and mortality over five years in patients with ASCVD but no prior ischemic events, highlighting their preventive potential in routine
This phase 3 trial demonstrates that the oral PCSK9 inhibitor enlicitide achieves significantly greater LDL-C reduction than bempedoic acid, ezetimibe, or their combination in statin-treated adults at elevated cardiovascular risk, with comp
Laroprovstat, an investigational oral PCSK9 inhibitor, was well tolerated and produced substantial LDL cholesterol reductions, especially when combined with rosuvastatin, supporting further development for hypercholesterolemia.
Registry data from 55,028 youths with type 1 diabetes show common LDL hypercholesterolemia, infrequent lipid-lowering therapy, and poor attainment of recommended LDL targets.
In a pooled nonrandomized phase 3 analysis, monthly lerodalcibep reduced LDL-C by about 50% in heterozygous familial hypercholesterolemia, with similar efficacy across LDLR functional variant categories and broad attainment of guideline-bas
This review synthesizes the trajectory of PCSK9 inhibitors, from pivotal monoclonal antibody trials to emerging RNA interference and gene-editing technologies, emphasizing their role in achieving ultra-low LDL-C levels and reducing major ad
This article explores the transformation of lipid management through PCSK9 inhibitors. From genetic discovery to landmark cardiovascular outcomes trials, we examine how monoclonal antibodies, RNA interference, and gene editing are redefinin
A landmark Norwegian study reveals that umbilical cord LDL-C levels overlap significantly between FH and non-FH newborns, making birth screening unreliable. In contrast, LDL-C becomes highly discriminative after age one, suggesting that uni
A large-scale multi-ancestry genetic study confirms consistent associations between LDL cholesterol levels and coronary artery disease risk across six global ancestries, highlighting the generalizability of LDL-C lowering interventions beyo
A 30-year prospective study reveals that elevated hsCRP, LDL cholesterol, and lipoprotein(a) levels independently and collectively increase the risk of ischaemic stroke in healthy women, advocating for early biomarker screening in stroke pr
This study finds an unexpected association between low levels of apolipoprotein B and LDL-cholesterol with increased all-cause and cardiovascular mortality, highlighting the complex role of lipid markers in mortality risk assessment.
The NEWTON-CABG CardioLink-5 trial found that intensive LDL-C lowering with evolocumab did not improve saphenous vein graft patency 24 months after coronary artery bypass surgery despite significant LDL-C reductions.
Obicetrapib significantly reduces LDL cholesterol by nearly 30% in high-risk cardiovascular patients on maximal lipid therapy, with a safety profile comparable to placebo, representing a potential novel agent in managing familial hyperchole
A 12-week randomized controlled trial demonstrated that supplementation with berberine plus cinnamon significantly lowers fasting blood sugar, HbA1c, and LDL cholesterol in patients with type 2 diabetes, offering potential for improved card
Evolocumab significantly lowers LDL cholesterol and substantially reduces cardiovascular events in patients with autoimmune/inflammatory diseases alongside statin therapy, according to the FOURIER trial analysis.
